Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2026)

Syndax Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $62.8 million for Q1 2026.

• On a quarterly basis, Receivables rose 141.4% year-over-year to $62.8 million in Q1 2026; TTM through Mar 2026 was $62.8 million, a 141.4% increase from a year earlier, with the FY2025 full-year figure at $66.1 million, up 488.2% from the prior year.
• Receivables grew to $62.8 million in Q1 2026 per SNDX's latest filing, from $44.4 million in the prior quarter.
• Across five years, Receivables topped out at $62.8 million in Q1 2026 and bottomed at $1.2 million in Q4 2023.
• The 4-year median for Receivables is $36.1 million (2025), against an average of $32.6 million.
• Across the five-year window, Receivables surged 815.81% in 2024 and soared 141.4% in 2026, its largest moves.
• Year by year, Receivables stood at $1.2 million in 2023, then jumped by 815.81% to $11.2 million in 2024, then soared by 295.12% to $44.4 million in 2025, then jumped by 41.48% to $62.8 million in 2026.
• Per Business Quant, the three latest SNDX Receivables figures stand at $62.8 million (Q1 2026), $44.4 million (Q4 2025), and $46.3 million (Q3 2025).